• NL close
• CN close
• SG close
• DZ close
• HK close
• Thematic: No close

NODE (The National Omics Data Encyclopedia) provides an integrated, compatible, comparable, and scalable multi-omics resource platform that supports flexible data management and effective data release. NODE uses a hierarchical data architecture to support storage of muti-omics data including sequencing data, MS based proteomics data, MS or NMR based metabolomics data, and fluorescence imaging data. Launched in early 2017, NODE has collected and published over 900 terabytes of omics data for researchers from China and all over the world in last three years, 22% of which contains multiple omics data. NODE provides functions around the whole life cycle of omics data, from data archive, data requests/responses to data sharing, data analysis, data review and publish.

mirDNMR is a database for the collection of gene-centered background DNMRs obtained from different methods and population variation data. The database has the following functions: (i) browse and search the background DNMRs of each gene predicted by four different methods, including GC content (DNMR-GC), sequence context (DNMR-SC), multiple factors (DNMR-MF) and local DNA methylation level (DNMR-DM); (ii) search variant frequencies in publicly available databases, including ExAC, ESP6500, UK10K, 1000G and dbSNP and (iii) investigate the DNM burden to prioritize candidate genes based on the four background DNMRs using three statistical methods (TADA, Binomial and Poisson test). In conclusion, mirDNMR can be widely used to identify the genetic basis of sporadic genetic diseases.

FerrDb V2 contains 1001 ferroptosis regulators and 143 ferroptosis-disease associations manually curated from 3288 articles. Specifically, there are 621 gene regulators, of which 264 are drivers, 238 are suppressors, 9 are markers, and 110 are unclassified genes; and there are 380 substance regulators, with 201 inducers and 179 inhibitors. Compared to FerrDb V1, curated articles increase by > 300%, ferroptosis regulators increase by 175%, and ferroptosis-disease associations increase by 50.5%. Circular RNA and pseudogene are novel regulators in FerrDb V2, and the percentage of non-coding RNA increases from 7.3% to 13.6%. External gene-related data were integrated, enabling thought-provoking and gene-oriented analysis in FerrDb V2.

The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

NSSDC is the nation-level space science center which recognized by the Ministry of Science and Technology of China. As a repository for space science data, NSSDC assumes the responsibility of the long-term stewardship and offering a reliable service of space science data in China. It also has been the Chinese center for space science of the World Data Center (WDC) since 1988. In 2013, NSSDC became a regular member of World Data System. Data resources are concentrated in the following fields of space physics and space environment, space astronomy, lunar and planetary science, space application and engineering. In space physics, the NSSDC maintains space-based observation data and ground-based observation data of the middle and upper atmosphere, ionosphere and earth surface, from Geo-space Double Star Exploration Program and Meridian Project. In space astronomy, NSSDC archived pointed observation data of Hard X-ray Modulation Telescope. In lunar and planetary science, space application and engineering, NSSDC also collects detection data of Chang’E from Lunar Exploration Program and science products of BeiDou satellites.

Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.